Posts

Insmed Shelves Brinsupri for Hidradenitis Suppurativa After Phase 2b Failure

on

Insmed's Arikayce Achieves Phase 3 Success in MAC Lung Disease, Paving Way for Label Expansion and Potential Blockbuster Status

on

Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

on

2026 Insmed Summer Internship Program in AI-Based Protein Design

on

Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease

on

Insmed's Brinsupri Receives First-Ever FDA Approval for Progressive Lung Disease

on

Insmed's 'Unprecedented' Phase 2 PAH Results Propel Stock and Next-Phase Plans

on

Insmed's TPIP PAH Therapy Advances to Phase III Following Positive Phase 2b Results

on